Bicycle Therapeutics
BCYC
106 hedge funds and large institutions have $886M invested in Bicycle Therapeutics in 2022 Q1 according to their latest regulatory filings, with 25 funds opening new positions, 27 increasing their positions, 42 reducing their positions, and 19 closing their positions.
320% more call options, than puts
Call options by funds: $28.8M | Put options by funds: $6.85M
32% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 19
6% more funds holding
Funds holding: 100 → 106 (+6)
5.07% less ownership
Funds ownership: 73.3% → 68.23% (-5.1%)
25% less funds holding in top 10
Funds holding in top 10: 8 → 6 (-2)
32% less capital invested
Capital invested by funds: $1.31B → $886M (-$426M)
36% less repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 42
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$35.3M |
| 2 |
EC
EcoR1 Capital
San Francisco,
California
|
+$25.6M |
| 3 |
RI
RTW Investments
New York
|
+$19M |
| 4 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$16.4M |
| 5 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$8.17M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tybourne Capital Management
Hong Kong
|
-$42M |
| 2 |
FM
Frazier Management
Seattle,
Washington
|
-$33.8M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$30.7M |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
-$6.66M |
| 5 |
IC
Ikarian Capital
Dallas,
Texas
|
-$6.27M |
BCYC Hedge Fund Activity: Q1 2022 in Review
106 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in Bicycle Therapeutics (BCYC) for Q1 2022, worth a combined $886M — down 32% from $1.31B a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new BCYC positions and 19 closed out — a net gain of 6 holders — while 27 added to existing stakes and 42 trimmed.
The largest buyer was Deep Track Capital, adding an estimated $35.3M. The largest seller was Tybourne Capital Management, cutting an estimated $42M.
- 106 institutional investors held Bicycle Therapeutics (BCYC) as of Q1 2022, up from 100 in Q4 2021.
- Funds reported $886M of Bicycle Therapeutics stock for Q1 2022, down 32% quarter-over-quarter.
- 25 funds opened new Bicycle Therapeutics positions in Q1 2022 and 19 closed out, a net change of +6 holders.
- The largest Bicycle Therapeutics buyer in Q1 2022 was Deep Track Capital, an estimated $35.3M added.
- The largest Bicycle Therapeutics seller in Q1 2022 was Tybourne Capital Management, an estimated $42M sold.
Based on aggregated 13F filings for Q1 2022.